Compare Royal Caribbean Cruises Ltd (RCL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs TG Therapeutics Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $259.9 (market cap $70.74B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 8.3× TG Therapeutics Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.27% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RCL | TGTX | |
|---|---|---|
Market Cap | $70.74B | $8.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.23 | $59.06 |
52-Week Low | $246.71 | $26.94 |
Enterprise Value | $93.38B | $8.74B |
Dividend Yield | 2.27% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
